Drug Profile
AVE 9633
Alternative Names: Anti-CD33 TAP; Anti-CD33-DM4 immunoconjugate; huMy9-6-DM4; huMY96DM4Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer ImmunoGen; Sanofi
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; CD33 antigen inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Europe (Parenteral)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (Parenteral)